Fluicell ABOSTO:FLUI +2.32%54 Piotroski F-Score is 4 as of Jul. 01, 2026, which is at its 10-year median of 4.00. GuruFocus rates OSTO:FLUI with a GF Score™ of 54/100 and a GF Value™ of kr34.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,337 Biotechnology companies, Fluicell AB ranks better than 74.2% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Fluicell AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Fluicell AB's Piotroski F-Score or its related term are showing as below:
OSTO:FLUI'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 6
Current: 4
During the past 11 years, the highest Piotroski F-Score of Fluicell AB was 6. The lowest was 2. And the median was 4.
Fluicell AB (OSTO:FLUI) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Fluicell AB Piotroski F-Score Related Terms
Fluicell AB Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Fluicell AB's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Fluicell AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Fluicell AB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Fluicell AB's current Net Income (TTM) was -2.35.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Fluicell AB's return on assets of this year was -0.1078598. Fluicell AB's return on assets of last year was -0.43932894.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Fluicell AB's current ratio of this year was 1.3338417. Fluicell AB's current ratio of last year was 2.81500672.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Fluicell AB's number of shares in issue this year was 1.374. Fluicell AB's number of shares in issue last year was 0.917.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Fluicell AB's gross margin of this year was 1.52448378. Fluicell AB's gross margin of last year was 3.2783738.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Fluicell AB's asset turnover of this year was 0.54504111. Fluicell AB's asset turnover of last year was 0.07521767.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
0
+
0
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Fluicell AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Fluicell AB (OSTO:FLUI) has a Piotroski F-Score of 4 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Fluicell AB and its competitors. This is near median its historical median of 4.00. Over the past decade, Fluicell AB's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Fluicell AB ranks #345 out of 1337 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Fluicell AB's Piotroski F-Score too high?
Fluicell AB's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Fluicell AB's value of 4 is 33.3% above this industry median. Based on the distribution chart, Fluicell AB ranks #345 out of 1337 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #345 out of 1337 companies for Piotroski F-Score. This puts Fluicell AB in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Fluicell AB's value of 4 is 33.3% above this benchmark. Historically, Fluicell AB's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Fluicell AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,337 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.58, compared to a current price of kr30.90 — trading 10.6% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Piotroski F-Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr30.90 is trading 10.6% below its estimated GF Value™ of kr34.58.
GuruFocus considers Fluicell AB to be Modestly Undervalued.
Key valuation signals for OSTO:FLUI:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: kr34.58 vs. price of kr30.90 (10.6% below fair value)
Industry Position: 33.3% above the Biotechnology median (#345 of 1337)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for OSTO:FLUI
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
